Incretin Secretion in Women With Polycystic Ovary Syndrome (PCOS)

Hvidovre University Hospital

Status: Terminated

Conditions: Polycystic Ovary Syndrome

Treatments: Drug: metformin

Study type: Interventional

Funder types: Other

Identifiers

NCT00647023

Incretins and PCOS

Details and patient eligibility

About

The incretin hormones are secreted from the gastrointestinal tract in response to nutrient ingestion, and are responsible for 70 % of insulin secretion in response to glucose. The incretin response is attenuated in subjects with type 2 diabetes and other conditions associated with insulin resistance. Polycystic ovary syndrome (PCOS) is characterised by irregular periods and increased androgen levels. It is the most common endocrine disorder amongst young women at fertile age, and the most common cause of female infertility. Insulin resistance plays an important role in the development of the disease, and women with PCOS are at increased risk of developing tyoe 2 diabetes. the incretin hormones have not previously been investigated in women with PCOS, and the purpose of the present study was to investigate the secretion of the two most important incretin hormones Glucose-like peptide-1 (GLP-1) and Glucose dependent insulinotropic peptide (GIP) during a three hour oral glucose tolerance test.

Enrollment: 66 patients

Sex: Female

Ages: 18 to 38 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subjects who fulfill the Rotterdam criteria for PCOS. Age 18-38

Exclusion criteria

• Other endocrine diseases or diseases known to influence glucose/insulin/fat metabolism
• Oral contraceptive administration within three months of study start

Trial design

66 participants in 1 patient group

A

Experimental group

Treatment:

Drug: metformin